Premier Alternatives

Mercy BioAnalytics

Waltham, MA · Founded 2018 · Privately Held (backing)

Developer of a novel liquid biopsy assay platform designed to relieve suffering and save lives through the early detection of cancer. Mercy BioAnalytics is based in Waltham, MA and was founded in 2018. It was valued at $122 million at its later-stage round in Mar 2023, the last priced event on record. It has raised $127 million across 1 recorded round; the latest was a $27.3 million early-stage round in Nov 2020.

PMV mark · valuation
$122.0M
Oct 2026
Priced at
its later-stage round
Mar 2023
Total raised
$127.3M
Last round
Early Stage VC
Nov 2020

Mercy BioAnalytics key facts

as of Oct 2026
  • Developer of a novel liquid biopsy assay platform designed to relieve suffering and save lives through the early detection of cancer.
  • Mercy BioAnalytics is valued at approximately $122.0M as of Oct 2026, set at its later-stage round, Mar 2023; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $127.3M across 1 recorded rounds; the latest was Early Stage VC ($27.3M) in Nov 2020.
  • Notable investors include New Enterprise Associates, Jump Capital, Labcorp Venture Fund, Hatteras Venture Partners, iSelect Fund — 25 tracked in total.
  • Mercy BioAnalytics has filed 1 Form D with the SEC, most recently Feb 2021 ($27.3M sold to 57 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$122.0M

Valued at $122.0M at its later-stage round, Mar 2023. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Mercy BioAnalytics with a free account
  • ·The complete investor list: 25 names
  • ·Watch Mercy BioAnalytics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Mercy BioAnalytics funding rounds

1 rounds
Nov 2020Early Stage VC$27.3MSEC filing▮
Full funding history →

Mercy BioAnalytics valuation

Mercy BioAnalytics was valued at $122 million at its later-stage round in Mar 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Mercy BioAnalytics raised?

Mercy BioAnalytics has raised $127 million in total; 1 of its rounds is on record. The largest on record was a $27.3 million early-stage round in Nov 2020.

Mercy BioAnalytics has filed 1 Form D with the SEC, most recently in Feb 2021 ($27.3 million sold to 57 investors).

Mercy BioAnalytics investors

25 investors are on record for Mercy BioAnalytics, including New Enterprise Associates, Jump Capital, Labcorp Venture Fund and Hatteras Venture Partners. By type, the record holds 9 venture capital firms and 1 hedge fund. The early-stage round in Nov 2020 drew 57 investors.

About Mercy BioAnalytics

Developer of a novel liquid biopsy assay platform designed to relieve suffering and save lives through the early detection of cancer. The company's platform interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling patients to detect various types of cancer at the earliest stages.

Sector
Healthcare
HQ
Waltham, MA, United States
Founded
2018
Employees
47
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.